Valeant Left Out, Actavis Acquires Allergan in $66B Deal

The transcript discusses Valiant's offer and its implications for shareholders, noting that the acquirer's stock is up, indicating investor approval. It explores potential future mergers in the pharmaceutical space, particularly inversion deals, and highlights trends in biotech and pharma investments. The discussion also predicts growth in the animal health market, emphasizing its global significance beyond pets.

What factors might influence Valiant's decision to adjust their offer price?

How did investors react to the news about the deal involving Valiant?

What implications does the recent deal have for future mergers in the pharmaceutical industry?

What role do hedge funds play in pharmaceutical mergers and acquisitions?

Discuss the significance of the animal health market in relation to pharmaceutical mergers.